ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Terminated

Phase 3 Results N/A

Summary of Purpose

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months. Trial Stopped: Futility

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 January 2010.

1 Mar 2006 6 Mar 2006 1 Dec 2008 1 Dec 2008 1 Jan 2010 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Vicki Higham Phone: 201-941-8807 Email: vhigham@ntii.com Phone: 1-866-end2cva

    vhigham@ntii.com